AABB Audioconferences:

Delivering Quality Education Directly to Your Facility… and to You

Advancing Transfusion and
Cellular Therapies Worldwide

2009

audioconference series

introduction

AABB recognizes that advancing the skills and knowledge of professionals working in blood centers, hospital blood banks, transfusion services, testing laboratories and cellular therapy facilities is a top priority. Even with decreased education training budgets, it is essential to provide these educational opportunities without interrupting the daily flow of business.

AABB audioconferences afford professionals in transfusion medicine and cellular and related biological therapies the opportunity to obtain timely information from recognized experts in the field. Keeping individuals and facilities up-to-date on current standards, accreditation requirements, medical and scientific advances as well as administrative and management practices is paramount to AABB's educational mission. For less than the average cost of sending one person to an out-of-town conference, you can train your entire staff by registering as a host site for an AABB audioconference.

Cellular Therapy Focus

Audioconferences focused on cellular therapy are denoted with a CT.

Educational Benefits: Continuing Education Credit

Access Your CEs Online!

All audioconference participants will be granted access to their CE credits and attendance verifications online after completing a short evaluation. All credits will be personalized, tracked and maintained online so that participants can access their records at any time. Simply fill in the attendance sheet with the necessary information (including an e-mail address for each participant) and visit the Live Learning Center at www.aabb.org at least 48 hours following the conclusion of the audioconference. Only those participants who signed the attendance sheet will be granted the appropriate continuing education credits.

Continuing Medical Education Credit: AABB is accredited by the Accreditation Council on Continuing Medical Education (Provider #0000381) to provide continuing medical education for physicians. AABB designates each audioconference for a maximum of 1.5 contact hours in Category 1 credit toward the American Medical Association Physicians' Recognition Award. Each physician should claim only those credit hours spent in the activity.

California Nursing Continuing Education Credit: AABB is approved by the California Board of Registered Nursing (Provider Number 4341) as a provider of continuing nursing education activities. AABB designates each audioconference for a maximum of 1.8 contact hours. California nurses must provide a personal signature and other required information on the attendance form.

California Clinical Laboratory Personnel Continuing Education Credit: AABB is an approved accrediting agency for continuing education for California-licensed clinical laboratory personnel. Each audioconference has been approved for a maximum of 1.5 contact hours. AABB's accrediting agency number is 0011. California clinical laboratory personnel must provide a personal signature and other required information on the attendance form. Credit earned through attendance at audioconferences may be used to fulfill the state requirement for continuing education hours to maintain licensure status.

Florida Clinical Laboratory Personnel Continuing Education Credit: AABB is approved by the Florida Board of Clinical Laboratory Personnel, Provider Number 50-4261-1, as a provider of continuing education programs for Florida-licensed clinical laboratory personnel. Each audioconference has been approved for a maximum of 1.8 contact hours. Florida clinical laboratory personnel must provide a personal signature and other required information on the attendance form.

Perfusionist Continuing Education Units: AABB is approved by the American Board of Cardiovascular Perfusion (ABCP) as a provider of Category 1 credit to those perfusionists who attend audioconferences. ABCP allots a maximum of 1.8 continuing education units for each audioconference. Perfusionists must sign in to verify attendance in order to receive contact hour credit for educational activities.

International Participants

Ireland: The Professional Enhancement Program (PEP) of the Irish Academy of Medical Laboratory Sciences will offer credit for AABB audioconferences. PEP registrants who participate within the Blood Transfusion Service Board will receive PEP certificates of attendance at no additional charge.

United Kingdom: The Institute of Biomedical Science (IBMS) in the United Kingdom accredits AABB for Continuing Professional Development. Those who have registered on the IBMS Scheme will earn 0.2 educational category credits toward the annual 4.0 credit requirement. Participants are asked to use reference # TS011N98.

Questions regarding continuing education credits should be directed to the AABB Education Department at +1.301.215.6482 or education@aabb.org. Registration information appears at the end of this calendar.

Interlaboratory Comparisons in the Field of Cellular Therapy CT

Content for this program was developed in cooperation with BEST.

Program # 094569

January 7, 2009

2:00 pm to 3:30 pm (ET) 7:00 pm to 8:30 pm (GMT)

Director: Zbigniew M. Szczepiorkowski, MD, PhD, FCAP, Director, Cellular Therapy Center, Dartmouth-Hitchcock Medical Center

Faculty: Hermann Eichler, MD, Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University Medical School, Homburg, Germany; Derwood Pamphilon, MD, National Blood Service, Bristol, the United Kingdom; Zbigniew M. Szczepiorkowski, MD, PhD, FCAP, Dartmouth-Hitchcock Medical Center, Lebanon, NH

Intended Audience: Technologists, Scientists

Objectives:

- Learn about the spectrum of interlaboratory multisite studies performed by BEST members.
- Understand the complexities of interlaboratory comparison studies.
- Recognize different approaches to standardization of laboratory testing in cellular therapy.

Event Description: This program will focus on multisite studies performed under the auspices of the BEST Collaborative, a group of both academic and manufacturer members interested in addressing various topics related to transfusion medicine and cellular therapy. There are four teams: conventional components, transfusion safety, cellular therapy and clinical trials. The rapidly growing field of cellular therapy has been challenged with comparisons between different laboratories. The first challenges were uncovered with measurement of CD34 expression on hematopoietic progenitor cells. Significant discrepancies were identified, and several approaches were proposed to standardize this test. This audioconference will present results of several studies performed by the members of the cellular therapy team of the BEST Collaborative. These studies encompass HPC, Cord Blood, Apheresis, and TC, Dendritic Cells and consist of results based on the intralaboratory testing, interlaboratory testing and other sources of information such as broad surveys of the cellular therapy field.

Event Level: Intermediate to Advanced

CT *Cellular Therapy-focused audioconference.*

ISBT 128 for Cellular Products, Tissues, Derivatives and Beyond CT

Program # 094570

January 14, 2009

2:00 pm to 3:30 pm (ET) 7:00 pm to 8:30 pm (GMT)

Director/Moderator: Veronica Lewis, MS, MT(ASCP)SBB, Assistant Professor/ Director, SBB Certificate Program, Rush University

Faculty: D. Michael Strong, PhD, President, StrongSolutions; Pat Distler, MS, MT(ASCP)SBB, Technical Director, CCBBA, Inc; Adrian Gee, PhD, MIBiol, Professor of Medicine and Pediatrics, Director, GMP Facilities, Texas Children's Hospital

Intended Audience: Physicians, Scientists, Technologists, Managers/ Supervisors

Objectives:

- Review the status of ISBT 128 implementation in the field of cellular therapy and discuss obstacles involved with the implementation and selection of appropriate product codes.
- Describe how standardization in tissues and the use of ISBT 128 supports the goal of traceability.
- Describe the progress being made to extend ISBT 128 to applications beyond the labeling of blood.
- Outline the work being done to harmonize the ISBT 128 Standard with that of GS1, a supply chain standard used in labeling pharmaceuticals and other items.

Event Description: In this program, faculty will review the status of ISBT 128 implementation in the fields of cellular therapy, tissue transplantation and derivatives worldwide. Discussion will include current and potential experience with using ISBT in these specialties. The presentation will be based on information available at the time of the audioconference. Speakers will discuss the advantages and obstacles involved with the implementation of ISBT 128 as well as how to select appropriate product codes. Tools that are available to simplify the selection of product codes will be demonstrated. Application of ISBT 128 to products drawn for the National Marrow Donor Registry will be presented. Efforts to integrate ISBT 128 from various patient service providers, as well as the use of ISBT 128 in electronic messaging between disparate computer systems and newer delivery mechanisms such as RFID also will be discussed.

Event Level: Intermediate

CT *Cellular Therapy-focused audioconference.*

f e b r u a r y 0 9

Trends and Concerns: The Young Blood Donor and Adverse Reactions

Program # 094571

February 4, 2009

2:00 pm to 3:30 pm (ET) 7:00 pm to 8:30 pm (GMT)

Director/Moderator: Dennis Harpool, SBB(ASCP), Vice President of Manufacturing Systems, Blood Systems, Inc.

Faculty: Peter Tomasulo, MD, Chief Medical Officer, Blood Systems, Inc.

Intended Audience: Physicians, Nurses, Managers/ Supervisors

Objectives:

- Describe the concept of stratified rates of reactions and risks of reactions by donor characteristic.
- Review the relationship of blood volume and amount of blood donated to rate and risk of reaction.
- Identify possible interventions to reduce rates of donor reactions.

Event Description: In this program, faculty will review data regarding donor reactions and classify them by donor characteristics. It will focus on the donor's blood volume and 500 mL collections and the connections between age, gender and blood volume on donor reactions. Using the characteristics reviewed by the presenter, one organization's eligibility requirements to reduce donor reactions will be shared.

Event Level: Intermediate

Serologic Case Studies

Program # 094572

February 11, 2009

2:00 pm to 3:30 pm (ET) 7:00 pm to 8:30 pm (GMT)

Director: Kristina Williams, MT(ASCP)SBB, CQIA, CQA(ASQ), Manager, ARC IRL Operational Support, American Red Cross

Faculty: Teresa Harris, MT(ASCP)SBB, CQIA, CQA(ASQ), Manager, Immunohematology Reference Laboratory, NY-Penn/NEPA, American Red Cross; Laurie Delia, MT(ASCP)SBB, Manager, Immunohematology Reference Laboratory, NY-Penn/NEPA; Yolanda Sanchez, MT(ASCP)SBB, Consultation Supervisor, Education Coordinator and Instructor, Clinical Laboratory Science Program, Rush University Medical Center; Ann Viernes, MS, MT(ASCP)SBB, HP, Blood Bank Supervisor, Rush University Medical Center.

Intended Audience: Physicians, Technologists, Managers/Supervisors

Objectives:

- Assess patient diagnosis, history, and initial unexpected serology results in order to determine which additional serologic techniques are appropriate.
- List common techniques used in the blood bank laboratory for antibody detection and identification and be aware of differences among the techniques as they relate to serologic problem-solving.
- Evaluate serologic case studies in order to understand problem-solving paths.

Event Description: In the present-day blood bank laboratory, we are surrounded by options with testing methods. Commonly used testing methods may include tube, gel, and red cell solid phase testing. Testing may be performed by manual methods or by automated methods, and a blood bank laboratory may use multiple methods when problem-solving. This case studies presentation is intended to cover the multiple methods that are in widespread use. By presenting separate cases that highlight the use of varied methods, participants will be able to evaluate and understand the potential strengths and pitfalls of each method in regards to specificity and sensitivity in addition to improving overall serologic problem-solving skills.

Event Level: Intermediate

Donor Loyalty vs. Incentive Programs

Content for this program was developed in cooperation with the Association of Donor Recruitment Professionals (ADRP).

Program # 094573

February 25, 2009

2:00 pm to 3:30 pm (ET) 7:00 pm to 8:30 pm (GMT)

Director/Moderator: Loyce Holmes, MSM-PM, Business Design Manager, Haemonetics

Faculty: Susan Churchill, BS, Recruitment Coordinator, Mayo Clinic Donor Center

Intended Audience: Managers/Supervisors, CEOs/CFOs

Objectives:

- Provide an overview of allowable donor incentives, recognition efforts and donor loyalty programs.
- Differentiate between three strategies and the market drivers increasing the use of donor loyalty programs.
- Assess the impact on donor frequency rates as a result of moving to donor loyalty programs.

Event Description: Blood centers strive to create a feeling of faithfulness or allegiance to the blood center's mission of saving lives by developing strategies designed to build donor relations and encouraging them to become lifetime partners. There are several strategies available to blood centers: donor incentives, donor recognition efforts and donor loyalty programs. Is there a difference between incentives, recognition and loyalty programs? Don't loyalty programs include incentives and recognition? What is driving the move away from incentives and recognition to more three dimensional loyalty programs, and is this switch in strategy effective? This audioconference will address the differences in these approaches to increase donor participation and present the impact of each on donor frequency rates.

Event Level: Intermediate to Advanced

m a r c h 0 9

Unannounced Inspections of AABB and CAP: Ask Your Questions

Program # 094574

March 4, 2009

2:00 pm to 3:30 pm (ET) 7:00 pm to 8:30 pm (GMT)

Director: Denise M. Harmening, PhD, MT(ASCP), CLS(NCA), Professor, University of Maryland School of Medicine

Moderator: Barbara Bryant, MD, MT(ASCP)SBB, Medical Resident, NIH–Warren G. Magnuson Clinical Center

Faculty: Kathryn Petershagen, MT(ASCP)SBB, Blood Bank Supervisor, University of Texas Medical Branch; Daniel Madrigal, BSMT(ASCP)SBB, Quality Assurance Supervisor, University of Texas Medical Branch

Experts to Answer Questions: Holly Rapp, MT(ASCP)SBB, CQA(ASQ), CMQ/OE, Director of Accreditation and Quality, AABB; Denise Driscoll, MT(ASCP)SBB, Director, Laboratory Accreditation and Regulatory Affairs, College of American Pathologists

Intended Audience: Physicians, Scientists, Technologists, Managers/Supervisors, Quality Personnel

Objectives:

- Compare AABB assessments and CAP inspections.
- Describe alternative methods for performing assessments and inspections.

Event Description: Case studies will be presented to stimulate a question and answer session regarding AABB assessments and CAP inspections. Through an interactive process, program faculty will provide a review of the AABB and CAP accreditation processes. Participants are encouraged to share their strategies and suggestions for managing unannounced inspections.

Event Level: Intermediate

Red Cell Exchange vs. Red Cell Transfusion

Program # 094575

March 11, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director/Moderator: Patricia Jost Golden, RN, HP(ASCP)

Faculty: Haewon Kim, MD, Medical Director, Apheresis Service, Children's Hospital of Philadelphia

Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors

Objectives:

- Describe the goal of red cell transfusion and erythrocytapheresis therapy.
- Compare long-term erythrocytapheresis therapy to chronic simple transfusion therapy with respect to benefits vs. risks, especially in patients with sickle cell disease.

Event Description: The function of red blood cells (RBC) is to deliver oxygen to tissue. The primary goal of RBC administration is either to prevent hypoxia or improve tissue oxygenation. When the circulating red cell mass is reduced due to blood loss, reduced RBC production or increased RBC destruction, red cells are administered as a form of red cell concentrate (packed RBC) for anemia to prevent hypoxia or as whole blood for acute bleeding to restore circulating blood volume to prevent shock. When structurally or functionally abnormal red cells are present in the circulation, removal of those abnormal red cells may be the treatment of choice followed by replacement with normal RBCs. Specific and effective transfusion therapy should be carried out in each patient after evaluating clinical indications. This audioconference will provide an overview of red cell transfusion and red cell exchange. This program highlights pros and cons of long-term erythrocytapheresis and chronic RBC transfusion in sickle cell patients.

Event Level: Intermediate

Assays: Back to Basics (CT)

Program # 094576

March 18, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director/Moderator: Hanh Khuu, MD, Assistant Medical Director, Cell Processing Section, National Institutes of Health

Intended Audience: Technologists, Nurses, Managers/Supervisors

Objectives:

- Describe basic concepts about some assays performed in cell therapy laboratories including progenitor cell assay, trypan blue, automated and manual cell counting.
- Describe basic concepts about flow cytometry.
- Assess some assays used in more complex manufacturing processes such as use of a multisizer.

Event Description: Assays are sometimes under-appreciated for their important role in cell therapy laboratories. They are used to characterize the product, whether as the starting raw material or the final product infused to the patient. Assays range from automated cell counting, performed by most labs, to use of a multisizer cell counting instrument, required by some complex cell culture processes. This session will address some of the assays commonly performed in most cell therapy laboratories and stimulate interest in the under-appreciated, taken-for-granted area in cell therapy product manufacturing.

Event Level: Basic to Intermediate

(CT) *Cellular Therapy-focused audioconference.*

TRALI: Platelet/Plasma Strategies for Blood Centers and Hospitals

Program # 094577

March 25, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director/Moderator: Jerry Holmberg, PhD, MT(ASCP)SBB, Senior Advisor for Blood Safety and Executive Secretary for the Advisory Committee on Blood Safety and Availability

Faculty: Anne Eder, MD, PhD, Executive Medical Officer, American Red Cross; Louis Katz, MD, Executive Vice President, Medical Affairs, Mississippi Valley Regional Blood Center

Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors, Perfusionists

Objectives:

- Recall and explain various mitigation strategies to reduce the risk of TRALI.
- Evaluate the various strategies and describe the success of the AABB's recommendations to implement by November 2008.

Event Description: Transfusion Related Acute Lung Injury (TRALI) has been recognized as the leading reported cause of death in both male and female transfusion recipients. Associated with plasma-containing blood components, TRALI is thought to be the result of white blood cell antibodies in donors in which active granulocytes in the recipient's lungs cause pulmonary edema. AABB recommended that blood collecting facilities should implement interventions to minimize the preparation of plasma components from donors known to be leukocyte-alloimmunized or at increased risk of leukocyte alloimmunization. In addition, blood transfusion facilities were encouraged to implement appropriate evidence-based hemotherapy practices to minimize unnecessary transfusions. Monitoring of reported TRALI incidences as well as TRALI-related mortality was recommended for both the blood collection and transfusion facilities. These measures were to be implemented by November 2007 for whole blood and plasma components, and measures relating to platelet products were to be implemented in November 2008. Faculty will review the current status of TRALI, mitigation strategies and outcomes of those strategies.

Event Level: Intermediate

Review of Donor Testing and Confirmatory Tests

Program # 094578

April 1, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director/Moderator: Jennifer Rhamy, MBA, MA, MT(ASCP)SBB, HP, Vice President, Laboratory Services, Indiana Blood Center

Faculty: Jack Hager, MS, MT(ASCP)SBB, Director of Testing, American Red Cross National Testing Laboratory; Gene Robertson, PhD, Vice President, Donor Testing Services, Blood Systems Laboratories

Intended Audience: Technologists, Nurses, Managers/Supervisors

Objectives:

- List the mandated and commonly performed assays for blood donor screening and the reactive rates of each.
- Describe the confirmatory test for each of the blood screening assays.
- Name the equipment used for blood donor screening.
- Outline the role of Nucleic Acid Testing (NAT) versus serology in detecting the presence of infectious diseases in a blood donor.

Event Description: This audioconference is designed as a review of donor testing for those who are not actively working in a laboratory performing infectious disease testing. The speakers will review the methodology and performance of the current screening and confirmatory assays and their impact on blood safety.

Event Level: Basic to Intermediate

Coding and Reimbursement

Program # 094579

April 15, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director: Theresa Wiegmann, JD, Director, Public Policy, AABB

Faculty: William B. Lockwood, PhD, MD, Director, Transfusion Services and Tissue/Bone Bank, University of Louisville Hospital

Intended Audience: Physicians, Technologists, Managers/Supervisors

Objectives:

- Review new coding and billing rules, Medicare guidelines and instructions related to transfusion medicine services.
- Discuss transfusion services billing and reimbursement issues affecting hospitals today.
- Determine helpful ways to keep up with constantly evolving coding and reimbursement changes.

Event Description: Payment for blood and related services is subject to a complex array of difficult to understand coding and billing policies. The *AABB Billing Guide for Transfusion and Cellular Therapies* offers clear and concise explanations. In this program, attendees will be walked through the latest version of this guide. New coding and billing rules for blood products and related services will be explained. Attendees will have the opportunity to ask questions about transfusion medicine billing issues.

Event Level: Intermediate

Update on Allogeneic Hematopoietic Cell Transplantation CT

Content for this program was developed in cooperation with the American Society for Blood Marrow Transplantation (ASBMT).

Program # 094580

April 29, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director: Ginna G. Laport, MD, Assistant Professor, Division of Blood and Marrow Transplantation, Stanford University

Moderator: Robert S. Negrin, MD, Professor, Director, Blood and Marrow Transplant Program, Stanford Hospital and Clinics

Faculty: Ginna G. Laport, MD, Assistant Professor, Division of Blood and Marrow Transplantation, Stanford University; Steven M. Devine, MD, Associate Professor, Director, Blood and Marrow Transplant Program, Ohio State University; Krishna V. Komanduri, MD, Associate Professor, Stem Cell Transplantation and Transplant Immunology, The University of Texas MD Anderson Cancer Center

Intended Audience: Physicians, Technologists, Managers/Supervisors, Nurses, Scientists

Objectives:

- Discuss the expanding pool of hematopoietic cell sources.
- Provide background information on the biology of stem cell trafficking and egress.
- Discuss the role and summarize the clinical aspects of cytokines and chemokines in the mobilization of allogeneic stem cells with an emphasis on AMD3100 and novel agents.
- Present the background information on the biology of regulatory T cells, procurement and expansion and their expanding role in the allogeneic hematopoietic cell setting.

Event Description: The sources of allogeneic hematopoietic cells continue to grow. One speaker will discuss the data supporting the choice of either peripheral blood or marrow as an allogeneic stem cell source as well as alternative cell sources such as cord blood registries and haploidentical donors. With regards to the mobilization of allogeneic hematopoietic cell sources, G-CSF has been the standard for over a decade. But, the advent of newer agents, such as the CXCR4 antagonist, AMD3100, may change the standards of both autologous and allogeneic hematopoietic cell collection. Finally, regulatory T cells are a subset of lymphocytes that are increasingly being studied in adoptive immunotherapy protocols. This distinctive T cell population may play a vital role in controlling graft vs. host disease in the allogeneic transplant setting.

Event Level: Intermediate to Advanced

CT *Cellular Therapy-focused audioconference.*



m a y 0 9

Turning Data into Knowledge

Program # 094581

May 6, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director/ Moderator: Jerry Holmberg, PhD, MT(ASCP)SBB, Senior Advisor for Blood Safety and Executive Secretary for the Advisory Committee on Blood Safety and Availability

Faculty: Brian Custer, PhD, Assistant Investigator, Blood Systems Research Institute

Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors, CEOs/CFOs

Objectives:

- Analyze the problem, formulate the question and determine whether available data can be used to answer the question at hand.
- Describe processes to assess and improve the quality of data.
- Decide when data cannot be used.
- Determine pitfalls in the analysis of data and how the wrong analysis choice can lead to invalid answers.

Event Description: Data is power and contributes to knowledge, yet we surprise ourselves at the volume of data collected and more often are baffled at how to interpret the meaning of the data. Research and process improvement needs data, but if the objectives are not established before the collection, often the wrong parameters are collected. This leads to frustrations and delays. Analysis of data and turning that analysis into meaning is critical. This audioconference will identify the key to turning data into knowledge.

Event Level: Intermediate

Agents Used to Reduce Blood Utilization

Program # 094582

May 13, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director: Lorne Holland, MD, Associate Director of Transfusion Medicine, University of Colorado

Faculty: Jerrold H. Levy, MD, FAHA, Professor and Deputy Chair for Research, Emory University School of Medicine, Director of Cardiothoracic Anesthesiology, Emory Healthcare

Intended Audience: Physicians, Technologists, Managers/Supervisors

Objectives:

- List agents commonly used to reduce blood utilization.
- Explain the mechanisms by which these agents may reduce the need for blood transfusion.
- Discuss the benefits and risks of using these agents.

Event Description: A number of pharmacologic agents exist that may reduce, or completely eliminate, the need for transfusion. These drugs can help conserve scarce blood products and reduce the risk of adverse events associated with blood transfusion. Erythropoetin is a therapeutic option for chronically anemic patients in lieu of red cell transfusion. Antifibrinolytics may reduce blood usage, especially in extensive surgeries such as liver transplantation and cardiac bypass surgery. In the setting of trauma and massive transfusion, recombinant activated factor VII (rVIIa) has shown some success in reducing transfusion requirements. While these agents have a great potential to reduce blood utilization, they are not a panacea. Not all patients will respond to treatment and there is some risk for adverse events with use of these agents. These options will be addressed in this program.

Event Level: Intermediate

Transfusion Safety and Positive Patient ID at the Bedside

Program # 094583

May 20, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director: Shelvi McFadden, MT(ASCP), Technical Specialist, St. Lukes Hospital

Moderators: Shelvi McFadden, MT(ASCP), Technical Specialist, St. Lukes Hospital; Rodeina Davis, BS, Vice President and Chief Information Officer, BloodCenter of Wisconsin

Faculty: Lynne Briggs, BS, MA, Director, IT Applications, BloodCenter of Wisconsin; Frank Nizzi, MD, Medical Director of Technical Services, Carter BloodCare; Ralf Knels, MD, Vice Medical Director, Leader Manufacturing and Qualified Person, Institute Dresden, German Red Cross Blood Donation Service East, Chair, Eurocode International Blood Labeling System e.V., Chair, RFID Task Force, ISBT-Working Party "Information Technology"

Intended Audience: Physicians, Technologists, Nurses, Managers/ Supervisors

Objectives:

- Discuss the importance of transfusion safety.
- List and discuss mechanisms of achieving positive patient identification (ID) in transfusion service and at the bedside.
- Discuss the responsibility of transfusion service and nursing with regards to positive patient ID.
- Explore and discuss available technology for achieving positive patient ID at the bedside.

Event Description: Transfusion safety is the number one concern for clinicians and laboratory professionals when patients are transfused. Blood transfusions are given to improve a patient's clinical conditions. Positively identifying the patient before, during and after transfusion is necessary for ensuring the right product is given to its intended recipient. This session will explore all aspects of providing a safe transfusion to a patient with the use of positive patient ID.

Event Level: Intermediate



aabb audioconference series

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Hematology for Blood Bankers

Program # 094584

June 3, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director: Janet L. Vincent, MS, SBB(ASCP), Education Coordinator, University of Texas Medical Branch

Faculty: Brenda Barnes, MSEd, MT(ASCP)SBB, Transfusion Safety Officer, The Methodist Hospital; Chris LeVeque, MD, Medical Director, Blood Bank at Methodist Hospital

Intended Audience: Technologists

Objectives:

- Relate abnormal functions of hemostasis to the need for blood products.
- Provide examples of when RBCs, platelets, WBC, FFP and cryoprecipate are indicated for transfusion.
- Review the different tests done in hematology pertinent to the blood bank.

Event Description: Current transfusion therapy guidelines rely, in part, on hematology tests such as hemoglobin, hematocrit, prothrombin time (PT), and activated partial thromboplastin time (aPTT). However, what do all of these tests actually measure, and what do the results mean? After a basic review of the different tests conducted in hematology, the indications for blood products will be presented. Cases will be used to illustrate the concepts.

Event Level: Basic to Intermediate



Graft Versus Host Disease (GVHD): Pathophysiology, Clinical Manifestation and Current Management with Focus on Extracorporeal Photopheresis CT

Content for this program was developed in cooperation with the American Society for Apheresis (ASFA).

Program # 094585

June 10, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director/Moderator: Joseph Schwartz, MD, Director, Hemotherapy and Cellular Therapy Division of Transfusion Medicine, Columbia University Medical Center

Faculty: Paul Holland, MD, Clinical Professor of Medicine and Pathology, University of California at Davis Medical Center, Scientific Director, Delta Blood Bank; Mary Evelyn D. Flowers, MD, Director, Clinical LTFU, Associate Professor, UW, Associate Member Fred Hutchinson Cancer Research Center; Monica Bhatia, MD, Clinical Director, Impatient Pediatric Blood and Bone Marrow Transplantation, Assistant Clinical Professor of Pediatrics, Columbia University Medical Center, Morgan Stanley Children's Hospital of NY Presbyterian

Intended Audience: Physicians, Technologists, Nurses, Managers/ Supervisors

Objectives:

- Assess the pathophysiology of Graft Versus Host Disease and of Transfusion-Associated Graft Versus Host Disease.
- Evaluate the current treatment of Graft Versus Host Disease with focus on extracorporeal photochemotherapy (ECP).

Event Description: This audioconference will provide up-to-date information on Graft Versus Host Disease (GVHD). It will include a description of the disease, pathophysiology with special attention to Transfusion-Associated Graft Versus Host Disease (TA-GVHD) and current management with the recent results of use of photopheresis in patients with GVHD.

Event Level: Basic to Intermediate

CT *Cellular Therapy-focused audioconference.*

Emerging Infectious Diseases: Impact on the Donor Base

Program # 094586

June 17, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director/Moderator: Jennifer Rhamy, MBA, MA, MT(ASCP)SBB, HP, Vice President, Laboratory Services, Indiana Blood Center

Faculty: Louis M. Katz, MD, Executive Vice President, Medical Affairs, Mississippi Valley Regional Blood Center; Brian Custer, PhD, Assistant Investigator, Blood Systems Research Institute

Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors, CEOs/CFOs

Objectives:

- Name the emerging infectious agents that could impact the blood supply.
- Outline the screening assays available for detection of diseases potentially transmitted by transfused blood.
- Describe the risk and benefit potential of testing versus questioning versus no action for emerging diseases, including the impact of the actual disease on public health.

Event Description: What diseases represent an emerging threat to the blood supply? This audioconference will review several potential threats including babesiosis, dengue fever, malaria, and chikungunya. The speakers will review current and future options for screening diseases and the impact of potential loss of donors. Session faculty and participants also will look at the benefits, the public health impact and the costs associated with these diseases.

Event Level: Intermediate

Assessing the Quality and Effect of Transfused Red Blood Cells

Program # 094587

June 24, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director: Lorne Holland, MD, Associate Director of Transfusion Medicine, University of Colorado

Faculty: Jose A. Cancelas, MD, PhD, Director of Research Division, Hoxworth Blood Center, Associate Professor of Pediatrics, University of Cincinnati Academic Health Center

Intended Audience: Physicians, Technologists, Managers/Supervisors, Students/Fellows

Objectives:

- List commonly used preservative solutions and discuss the significant differences between them.
- Examine current methods to determine the quality of preserved red blood cells.
- Describe potentially better methods for determining the quality of preserved red blood cells.

Event Description: A great deal of effort has been put into perfecting preservation of red blood cells for transfusion. A simple solution of citrate, phosphate and dextrose (CPD) can be used to preserve red cells, but inclusion of additives (adenine, mannitol, etc.) will further extend the shelf-life of red blood cells. Currently, the effectiveness of a red cell preservative is determined by the amount of in vitro hemolysis prior to transfusion and then in vivo recovery the red cells after transfusion. However, simply assessing the survival of red cells does not provide information about the effectiveness of transfused red cells to function (i.e., deliver oxygen to tissues). This program will review the functional ability of transfused red cells that can be determined by a number of measures such as diphosphoglycerate (DPG), adenosine triphosphate (ATP) and nitrous oxide (NO) content. In addition, it will address future guidelines defining the acceptability criteria for preservative solutions that may include both measures of red cell survival and functional quality.

Event Level: Intermediate

Platelet Function Assays

Program # 094588

July 22, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director/Moderator: Jay H. Herman, MD, Director, Transfusion Medicine, Thomas Jefferson University Hospital

Faculty: Paula J. Santrach, MD, Consultant, Division of Transfusion Medicine, Mayo Clinic; Kenneth D. Friedman, MD, Director, Hemostatis Labs, BloodCenter of Wisconsin, Medical Director, Hemostasis Reference Laboratory, Blood Center of Southeastern Wisconsin

Intended Audience: Physicians, Scientists, Technologists

Objectives:

- Determine physiological impairments of platelet function.
- Describe the principles and methods used in and identify the diagnostic applications of platelet function testing.
- Discuss the role that testing plays in guiding platelet transfusion.

Event Description: Platelets play a role in multiple parts of the hemostatic mechanism, and both genetic and acquired disorders of aggregation, adhesion, activation, secretion and clot retraction have been described. In addition, drugs that impair platelet function are in common use in society, causing symptomatic hemorrhage as well as interference with the planning for surgery and invasive procedures. Platelet transfusion can play a key role in the correction of functional platelet impairment, and transfusion medicine services need to be aware of platelet function disorders. The principles of the testing that aid in the diagnosis and assessment of platelet function abnormalities will be reviewed in this audioconference, including methodologies at the point of care or the bedside as well as in coagulation laboratories. The role that these tests play in guiding platelet transfusion practice also will be reviewed.

Event Level: Basic



Established and Exotic Indications for Therapeutic Plasma Exchange

Program # 094589

July 29, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director/Moderator: Patricia Jost Golden, RN, HP(ASCP)

Faculty: Robert Weinstein, MD, Professor of Medicine and Pathology, University of Massachusetts Medical School

Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors, CEOs/CFOs

Objectives:

- List the most frequent indications for therapeutic plasma exchange in North America.
- Describe a process for assessing the application of plasma exchange to unproven therapeutic indications.
- Discuss potential new, evidence-based indications for therapeutic plasma exchange.

Event Description: This audioconference will cover the indications and goals of red blood cell exchange and simple red blood cell transfusion in the treatment of sickle cell anemia. The pros and cons of each therapeutic approach, such as ferritin levels and iron overload, antibody formation and viscosity will be discussed.

Event Level: Intermediate to Advanced

a u g u s t 0 9

What's New in Plasma Derived Components

Program # 094590

August 5, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director: Shelvi McFadden, MT(ASCP), Technical Specialist, St. Lukes Hospital

Moderators: Robertson Davenport, MD, Associate Professor, University of Michigan Hospitals; Shelvi McFadden, MT(ASCP), Technical Specialist, St. Lukes Hospital

Faculty: Larry J. Dumont, PhD, Director, Cell Labeling Laboratory, Dartmouth-Hitchcock Medical Center; Judi Miller, BSc, RGN, DPSN, VP Medical Affairs, Octapharma USA, Inc.

Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors

Objectives:

- Discuss the patient benefits and differences between 5-day and 7-day platelets.
- Describe the clinical indications of platelet therapy.
- List the types of products that can be produced from plasma.
- Describe the clinical benefits of SD plasma and discuss the differences between Plas+SD and Octaplas®.

Event Description: Plasma components are a vital piece of transfusion practice for patients today. As we continue to make safer products for patients through donor testing, we also continue to find new ways to produce the best product for the patient. This session will look at new plasma components for transfusion from production to distribution and finally administration. The faculty will explore the issues associated with 5-day platelets, 7-day platelets, solvent detergent plasma, products manufactured from plasma and the types of patients and spectrum and diversity of diseases/conditions treated with plasma derived products.

Event Level: Basic to Intermediate

State of the Science in Hematopoietic Cell Transplantation (HCT) CT

Content for this program was developed in cooperation with the National Marrow Donor Program (NMDP).

Program # 094591

August 12, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director/Moderator: John Miller, MD, PhD, Vice President and Medical Director, National Marrow Donor Program

Faculty: Dennis Confer, MD, Chief Medical Officer, National Marrow Donor Program; John Miller, MD, PhD, Vice President and Medical Director, National Marrow Donor Program

Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors

Objectives:

- Assess the most recent data on the impact of donor and recipient HLA matching on transplant outcome.
- Describe other non-HLA donor and patient factors that influence the outcome of HCT.
- Discuss what tools are available to assist you in choosing the best donor.

Event Description: Unrelated HCT has steadily grown over the past 20 years. This session will provide a scientific update on what we have learned about donors and their recipients and how we apply this knowledge to donor and patient selection today. What are the donor related factors that impact patient outcome and how do they guide donor selection? How have the patient populations treated with transplantation changed over time and have we improved overall survival, and if so, how? What are the hot topics of research to continue to advance the state of the art of HSC as we move forward? Learn possible answers to these key unanswered questions in clinical transplantation that are the focus of current and planned research.

Event Level: Intermediate to Advanced

CT *Cellular Therapy-focused audioconference.*

Serological Cases: Ask the Experts

Program # 094592

August 19, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director/Moderator: Denise M. Harmening, PhD, MT(ASCP), CLS(NCA), Professor, University of Maryland School of Medicine

Faculty: Susan Johnson, MSTM, MT(ASCP)SBB, Director, BloodCenter of Wisconsin; LeeAnn Prihoda, MEd, MT(ASCP)SBB, Manager, Reference Laboratory, American Red Cross - Southern Region

Intended Audience: Physicians, Scientists, Technologists, Managers/Supervisors

Objectives:

- Compare similarities and characteristics of solving multiple antibody problems.
- Describe the multiple antibody approach to ABO testing for hematopoietic stem cell transplantation patients and the selection of the appropriate ABO blood products.
- Evaluate serological test results and propose further testing needed to resolve serological problems.
- Relate accurate patient history to evaluation of serological test results.

Event Description: Case studies will be presented to stimulate a question and answer program regarding challenging serological scenarios. Through an interactive process, this program will address the similarities and characteristics of common serological testing problems encountered in the blood bank laboratory. Audience members are encouraged to share their strategies and suggestions for solving serological testing complications presented through a case history format.

Event Level: Intermediate to Advanced

s e p t e m b e r 0 9

To "D" or Not to "D:" Controversy Continues

Program #094593

September 2, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director/Moderator: Janet L. Vincent, MS, SBB(ASCP), Education Coordinator, University of Texas Medical Branch

Faculty: Beth Hartwell, MD, Medical Director, Gulf Coast Regional Blood Center; Jayanna Slayten, MS, MT(ASCP)SBB, IRL Manager, SBB Program Education Coordinator, Indiana Blood Center

Intended Audience: Physicians, Technologists, Managers/Supervisors

Objectives:

- Describe the unique challenges of typing for the D antigen in patients and donors.
- Outline the procedures used in D typing in different settings.
- Relate the controversies from the view of the physician, donor/patient and transfusion service.

Event Description: After reviewing the challenges of the D antigen for the donor and patient, the speakers will present the ways some facilities handle these situations. Problems for the physician, donor, patient, and hospital transfusion service will be discussed, and suggested solutions will be described.

Event Level: Intermediate

Transfusing the Chronic Patient Population

Program # 094594

September 9, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director/Moderator: Jay H. Herman, MD, Director, Transfusion Medicine, Thomas Jefferson University Hospital

Faculty: Samir Ballas, MD, FACP, Professor of Medicine and Pediatrics, Director, Sickle Cell Center, Cardeza Foundation for Hematologic Research, Jefferson Medical College, Thomas Jefferson University; Deborah Sesok-Pizzini, MD, MBA, Medical Director, Blood Bank, University of Pennsylvania; Sandra Nance, MS, MT(ASCP)SBB, Sr. Director, IRL, BioMedical Services, American Red Cross Blood Services

Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors

Objectives:

- Identify the indications for chronic transfusion therapy.
- Distinguish chronic transfusion objectives for different patient populations.
- Determine the special needs of the chronically transfused patient.
- Describe the differences in chronic transfusion for children and adults.
- Discuss the role that alloimmunization has on sickle cell severity.

Event Description: Chronic red cell transfusion plays an important role in the therapy of specific patient populations; those with insufficient erythropoiesis, stem cell disorders or thalassemic conditions and those with chronic hemolysis from hemoglobinopathies. Indications for chronic transfusion in these diverse populations are well defined for both children and adults, and will be reviewed in this audioconference. Chronic transfusion programs require many considerations not usually a part of acute transfusion practice: transfusion hemosiderosis, the long-term effects of red cell alloimmunization, consideration of "phenotype matching" and management of rare inventories, and the risk benefit of erythrocyte apheresis, to mention a few. The speakers will address these issues, along with the objectives of chronic transfusion in sickle cell disorders which differ from those for other patients. The role that alloimmunization to red cell antigens has in autoantibody formation and the increased hemolysis in sickle cell disease also will be addressed.

Event Level: Intermediate to Advanced

Evaluation and Validation Using Six Sigma

Program # 094595

September 16, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director/Moderator: Dennis Harpool, SBB(ASCP), Vice President, Manufacturing Systems, Blood Systems, Inc.

Faculty: Terri Poulin, MT(ASCP)SBB, Technical Director, United Blood Services; Bobbi Jewett-Keefe, MT(ASCP), Six Sigma Green Belt and Lean Certification, Customer Operations Consultant, Whole Blood Group, CaridianBCT

Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors, CEOs/CFOs

Objectives:

- Describe an enhanced validation process to evaluate a new automated component manufacturing device that uses Six Sigma methods.
- Compare conventional component manufacturing activities conducted at Blood Systems and the impact of a new device.
- Assess the integration of Six Sigma methods and the resultant outcomes.

Event Description: The method of validating a new process or instrument has been in place at Blood Systems for many years. Six Sigma methods were identified as an attractive means to assess new technologies while enhancing the interpretation of the results. This event addresses the approach Blood Systems has used to include Six Sigma tools and techniques in the design and implementation of validation activities. The method will be described along with an example validation case study.

Event Level: Intermediate

Legal Issues in Blood Banking: Real Case Studies

Program # 094596

September 23, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director/Moderator: Susan Connor, MBGM, MT(ASCP)SBB, Director of Physician Relations, John C. Lincoln Hospitals

Faculty: Ed Mansfield, JD, Belin Lamson McCormick Zumbach Flynn, PC, General Counsel, America's Blood Centers; Diane Killion, JD, Staff Counsel, AABB

Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors, CEOs/CFOs, Perfusionists

Objectives:

- Define the meaning of "negligence" in the blood center and transfusion litigation context.
- Review the status and impact of health care liability reform legislation.
- Discuss hot issues surrounding privacy and confidentiality.
- Determine legal issues relating to donor and patient informed consent.

Event Description: Blood centers and transfusion services operate in an environment where it is increasingly difficult to both strike a balance between the safety of donors and patients and manage the legal risks associated with operating those facilitates. Consequently, it is important for professionals to keep up with the latest legal developments. This audioconference will cover current legal issues relating to blood donations and transfusion.

Event Level: Intermediate

Twenty-First Century Donor Recruitment Tools

Program # 094597

September 30, 2009

2:00 pm to 3:30 pm (ET)

6:00 pm to 7:30 pm (GMT)

Director/Moderator: Loyce Holmes, MSM-PM, Business Design Manager, Haemonetics

Faculty: Maria Elena Geyer, MBA, Executive Vice President, Marketing and Community Relations, Puget Sound Blood Center; Shankar Goudar, MBA, Chief Information Officer, Carter Blood Care

Intended Audience: Managers/Supervisors

Objectives:

- Provide an overview of social networks and mass communication vehicles used for donor recruitment.
- Increase awareness of the pros and cons of 21st century recruitment technology.
- Review lessons learned and the impact of the use of technology in recruitment efforts.

Event Description: Social networks such as MySpace and FaceBook, along with mass communication tools like text messaging and podcasts, are becoming mainstream arsenal for many blood centers to increase donors. For many not-for-profit organizations, finding low-cost channels to communicate to large volumes of people with a positive return on investment is a challenge. Tapping into social networks and mass communication tools appears to be an attractive alternative to this dilemma. This audioconference will demonstrate how two blood centers ventured into these unchartered territories early in their market entry and describe their experiences.

Event Level: Intermediate to Advanced

Lessons Learned from the Battlefield: Use of Whole Blood and Blood Components

Program # 094598

October 7, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director/Moderator: Jerry Holmberg, PhD, MT(ASCP)SBB, Senior Advisor for Blood Safety and Executive Secretary for the Advisory Committee on Blood Safety and Availability

Faculty: Commander Charles C.M. Lelkens, MD, Commanding Officer and Medical Director, Military Blood Bank, The Netherlands; Jeremy Perkins, MD, FACP, Chief, Hematology-Oncology Clinic, Walter Reed Army Medical Center

Intended Audience: Physicians, Scientists, Technologists, Nurses, Perfusionists

Objectives:

- Describe various limitations and barriers in the battlefield that may be similar to everyday practice in any community.
- Discuss massive transfusions in combat casualties including transfusion rates and mechanisms of injury.
- Recall the various component therapies that are often used in massive battlefield trauma cases and how strategies change based on clinical condition as well as available component therapy.
- Compare the indication, advantages, disadvantages and outcomes of various strategies to control bleeding and oxygen delivery in the battlefield trauma cases.
- Discuss outcomes in massive transfusion relating various ratios of components given such as FFP:RBC ratios and platelet:RBC ratios.

Event Description: Throughout history, the experiences and challenges of treating the wounded on the battlefield have been a stimulus for advances in medicine. The field of transfusion medicine and component therapy has been the recipient of much experience, much based on necessity in the battlefield. Data driven indications for use of fresh whole blood (FWB) in trauma are unknown. Currently there are no randomized trials comparing whole blood to component therapy in the setting of trauma. FWB use is limited in the U.S., although the military routinely utilizes FWB in the setting of massive transfusion as both a source of platelets and other factors when large quantities of blood are required. Drawing from battlefield experience, the speakers of this audioconference will discuss challenges and strategies used in the battlefield. Discussion will include the use of component therapy, whole blood, and frozen blood in controlling hemostasis and maintaining oxygen delivery to the tissues in the wounded military and civilian patients.

Event Level: Intermediate to Advanced

Cellular Therapy Accreditation Update: Challenging CT Standards and Potential Solutions CT

Program # 094599

October 14, 2009

2:00 pm to 3:30 pm (ET) 6:00 pm to 7:30 pm (GMT)

Director/Moderator: Lynn O'Donnell, PhD, Director, Cell Therapy Laboratory, James Cancer Center, Ohio State University

Faculty: J. Wade Atkins, MS, MT(ASCP)SBB, Quality Assurance Specialist, National Institutes of Health; Elina Linetsky, MSc, MT, Director, Quality Assurance/Regulatory Affairs, cGMP Cell Transplant Center, DRI, University of Miami

Intended Audience: Technologists, Managers/Supervisors, Quality Personnel

Objectives:

- Discuss CT Standards for which facilities have requested clarification to assist in compliance.
- Learn about the most common citations and standards that often present challenges for facilities from CT assessors.
- Determine which standards facilities struggle with and what approaches have been towards compliance.

Event Description: The *Standards for Cellular Therapy Product Services*, 3rd edition were implemented in September of 2008. Are you confident that you truly meet the intent of every standard or are there some of which you would like additional background or information? Does your facility breeze through every assessment or do you struggle, unsure of how well you comply? If you are a CT assessor, would you like additional information on a specific standard? This session will draw on expertise from the AABB Cellular Therapy Standards and the Cellular Therapy Accreditation Program Units and also CT assessors to present examples of challenging CT standards and what facilities are doing to meet them.

Event Level: Basic to Intermediate

CT *Cellular Therapy-focused audioconference.*

Health Screening:
New Approaches to Donor Wellness

Program # 094600

November 4, 2009

2:00 pm to 3:30 pm (ET) 7:00 pm to 8:30 pm (GMT)

Director/Moderator: Dennis Harpool, SBB(ASCP), Vice President, Manufacturing Systems, Blood Systems, Inc.

Faculty: Stephen Eason, MBA, CFRE, Director of Development, Carter Blood Care; Merlyn Sayers, MD, PhD, President and CEO, Carter BloodCare

Intended Audience: Physicians, Nurses, Managers/Supervisors

Objectives:

- Identify the unique opportunity volunteer blood donation presents for health screening that is unrelated to reducing transfusion risk.
- Review the evidence that donor health screening provides concerning the risk for cardiovascular disease and diabetes.
- Determine how this information can provide valuable epidemiological information when analyzed by age, gender and ethnicity.

Event Description: More than 40,000 volunteer blood-donating Americans who regard themselves as healthy donate every day. If donation screening is supplemented with, for example, assays for total cholesterol and hemoglobin, then these individuals could gain valuable insights into health risks that might not otherwise have gained their attention. This session will demonstrate how providing this important information to donors can be a service to donors.

Event Level: Intermediate

RBC Genotyping—Molecular Testing

Program # 094601

November 18, 2009

2:00 pm to 3:30 pm (ET) 7:00 pm to 8:30 pm (GMT)

Director/Moderator: Jennifer Rhamy, MBA, MA, MT(ASCP)SBB, Vice President, Laboratory Services, Indiana Blood Center

Faculty: Connie Westoff, MT(ASCP)SBB, PhD, Scientific Director, Molecular Blood Group and Platelet Antigen Testing, American Red Cross

Intended Audience: Physicians, Scientists, Technologists, Managers/ Supervisors

Objectives:

- Discuss the physiologic functions of the proteins that carry blood group antigens in the red cells and other tissues.
- Cite the incidence of the antigen in the population, describing ethnic relationships.
- Describe how new protein modeling tools contribute to understanding structural changes to blood group antigens and impact production of antibodies.

Event Description: The evolution of molecular typing has given the industry new perspectives on the incidence and distribution of the individual antigens within the blood group systems. This program will describe the structure and function of molecules that carry red cell antigens and share what is being uncovered relative to the incidence of variants in different populations. The impact of mutations on the structure of known blood group antigens and implications for the practice of transfusion medicine will be discussed.

Event Level: Intermediate to Advanced

d e c e m b e r 0 9

Geek Squad for Blood Banking: Metrology

Program # 094602

December 9, 2009

2:00 pm to 3:30 pm (ET) 7:00 pm to 8:30 pm (GMT)

Director/Moderator: Veronica Lewis, MS, MT(ASCP)SBB, Assistant Professor/ Director, SBB Certificate Program, Rush University

Faculty: Charles Van Nort, MT(ASCP), Director, Validation & Equipment Management, Technical Services, American Red Cross; David Owens, Manager, Validation and Equipment Management, Technical Services, American Red Cross

Intended Audience: Scientists, Technologists, Managers/Supervisors

Objectives:

- Recall AABB and FDA regulations in regards to blood bank metrology equipment such as thermometers, scales and timers.
- List the types of blood bank metrology equipment used in blood banks and transfusion service laboratories.
- Discuss the concept of traceability.
- Describe good calibration practices and the level of accuracy required for metrology equipment used in blood banks and transfusion service laboratories.

Event Description: Weight, volume, time and temperature measurements are essential to blood bank and transfusion service operation. Applied metrology concerns the application of measurement science to manufacturing and industry, ensuring the suitability of measurement instruments, their calibration, and quality control of measurements. This program introduces the fundamentals of metrology as it applies to blood banking. AABB and FDA regulatory requirements will be reviewed. Types of metrology equipment used in blood banks and transfusion service laboratories will be described. Methods to ensure appropriate calibration and accuracy for blood banks will be discussed.

Event Level: Basic to Intermediate

CLIA Blood Banking Personnel Requirements

Program # 094603

December 16, 2009

2:00 pm to 3:30 pm (ET) 7:00 pm to 8:30 pm (GMT)

Director/Moderator: Susan Connor, MBGM, MT(ASCP)SBB, Director of Physician Relations, John C. Lincoln Hospitals

Faculty: Penny Meyers, MA, MT(ASCP)SBB, Medical Technologist, Centers for Medicare and Medicaid Services

Intended Audience: Physicians, Technologists, Managers/Supervisors, Quality Personnel

Objectives:

- Provide a brief overview of the CLIA regulating agency, its purpose and its intent.
- Discuss the applicability of the CLIA regulations to blood centers and transfusion services.
- Review the "deemed status" CLIA grants to six accreditation organizations and how to use this to maintain compliance.
- Review current hot topics and the CLIA regulations that apply.

Event Description: The blood bank industry is regulated by many agencies, which can make it challenging to understand the regulations as well as which agency, specifically, regulates the operations of the blood center and transfusion service. In this session, the CLIA (Clinical Laboratory Improvement Amendments) regulations that impact the blood industry will be reviewed. Discussion will include the testing regulated by CLIA and the personnel requirements to perform these tests in the blood center or transfusion service. Current hot topics and the regulations will also be addressed.

Event Level: Intermediate

aabb audioconference series

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

how to register

Setting Up an Audioconference is Quick and Easy

Educational programs delivered through this medium enable thousands of blood banking, transfusion medicine and cellular therapy professionals to learn the latest in the field, at the lowest price, in the most convenient location — your facility! Take advantage of the AABB's superior schedule of programs and register as an audioconference institutional host site.

To participate, your facility will need:

- A site coordinator.
- An amplified telephone.
- A projector.
- A screen.

AABB will provide your institution with access to everything else you need via e-mail, including a Web link to all instructions and handouts. Read on to learn more about how to bring an audioconference program to your location.

3 Easy Ways to Register:

Online:
Sign up online at www.aabb.org > Meetings and Events > Audioconferences.

By Fax:
Complete the registration form (either the Facility or the Individual Registration Form) at the back of the calendar and fax to +1.301.907.6895.

By Mail:
Complete the registration form at the back of the calendar and mail to:

AABB Education Department
8101 Glenbrook Road
Bethesda, MD 20814-2749 USA

Once your registration is received, you will be sent all of your audioconference instructions and materials via e-mail.

Host Site Materials

Audioconference site coordinators will be asked to download audioconference materials from a Web site via a link that will be e-mailed to you. You will be able to access and download all slides, handouts and other materials from one convenient location and print them right from your own computer.

Requirements for Using the Downloaded Files

- A desktop or laptop computer with the latest version of Adobe Acrobat Reader.
- A printer attached to the computer to print a master set of handouts.
- An LCD projector and projection screen, or a television monitor for displaying presentation slides.
- A video card or other video output device attached to the computer (if using a television monitor).

Facility Host Site Coordinator Responsibilities

- Obtain a room for the program.
- Arrange for the necessary equipment.
- Telephone the telecommunications company 10–20 minutes before the start of the program.
- Submit participant lists online within 48 hours of the completion of an audioconference to give attendees online access to personalized credits and attendance certificates in the AABB Live Learning Center.

Toll-Free Access

After registering, each host site coordinator or individual will be e-mailed a toll-free telephone number and a separate password, which gives you access to the specific audioconference.

Questions?

Please call us at +1.301.215.6482 or education @aabb.org.

Facility Host Site Guidelines

- Site Coordinators and individual participants should not give their audioconference access numbers or password to any other facility or individual. Only one line is allowed per registration. Any additional lines will be billed after the audioconference.
- There should be no outside recording of the audioconference by individuals or facilities without the express written permission of AABB.
- Conference materials are protected by copyright. The PDF files are the property of AABB. The Adobe Acrobat Reader installation file is the property of Adobe Systems Incorporated. Please consult AABB and/or Adobe regarding permission to reproduce and distribute these materials.

Registration Updates

Visit www.aabb.org > Meetings and Events > Audioconferences.

Cancellation Policy

All cancellations must be made in writing and sent to education@aabb.org. Cancellations received by AABB at least two weeks prior to a program will receive a full refund less a $75 administrative fee. There will be no refunds for cancellations within two weeks of an audioconference.

Facility Registration Form

Host Site Registration Fees: *(All fees are per audioconference.)*

	Single Audioconference	8+ Audioconferences
Institutional Member	$330	$315 Best Rate!
Institutional Nonmember	$380	$365

To take advantage of the package savings, you must register for all of your audioconference selections at the same time. Payment is due in advance.

Register my facility as a host site for the following 2009 Audioconferences: *(check all that apply)**

❑ 094569 January 7	❑ 094578 April 1	❑ 094587 June 24	❑ 094596 September 23
❑ 094570 January 14	❑ 094579 April 15	❑ 094588 July 22	❑ 094597 September 30
❑ 094571 February 4	❑ 094580 April 29	❑ 094589 July 29	❑ 094598 October 7
❑ 094572 February 11	❑ 094581 May 6	❑ 094590 August 5	❑ 094599 October 14
❑ 094573 February 25	❑ 094582 May 13	❑ 094591 August 12	❑ 094600 November 4
❑ 094574 March 4	❑ 094583 May 20	❑ 094592 August 19	❑ 094601 November 18
❑ 094575 March 11	❑ 094584 June 3	❑ 094593 September 2	❑ 094602 December 9
❑ 094576 March 18	❑ 094585 June 10	❑ 094594 September 9	❑ 094603 December 16
❑ 094577 March 25	❑ 094586 June 17	❑ 094595 September 16	❑ Other_____ *(please include program number and date of audioconference)*

** The audioconferences listed in this pamphlet are subject to change based on faculty availability and schedules.*

Please provide the following information: *(All fields are required)*

Facility Name: _____

Site Coordinator *(Individual name)*: _____

Site Coordinator's Title: _____

Shipping Address: _____

(No P.O. Boxes)

City/State/Zip: _____

Phone: _____ Fax: _____

E-mail: _____

AABB Institutional Membership Number*: _____

**If you are an Institutional Nonmember, please e-mail education@aabb.org for an identification number.*

All host site materials and instructions will be provided via e-mail.

Method of Payment:

Total Payment: _____ ***(Full payment must accompany registration form.)***

❑ Check Enclosed *(Payable to AABB and in US currency)*

❑ VISA/MasterCard ❑ Diners Club ❑ Discover ❑ American Express

Credit Card #: _____ Exp. Date: _____

Signature: _____ Name as printed on card: _____

Source Code *(in yellow box on mailing panel)*: _____

Register Now!

3 Easy Ways to Register:

Online:
www.aabb.org
>Meetings and Events
>Audioconferences

By Fax:
+1.301.907.6895

By Mail:
AABB Education Department
8101 Glenbrook Road
Bethesda, MD 20814-2749 USA

Registration Updates

Visit www.aabb.org
>Meetings and Events
>Audioconferences

Questions?

Contact the AABB Education Department at +1.301.215.6482 or education@aabb.org.

Cancellation Policy

All cancellations must be made in writing and sent to education@aabb.org. Cancellations received by AABB at least two weeks prior to a program will receive a full refund less a $75 administrative fee. There will be no refunds for cancellations within two weeks of an audioconference.

Advancing Transfusion and Cellular Therapies Worldwide

attention individuals

2009 Leadership Management Audioconference Series for Individuals

The Leadership Management Audioconference Series was developed in response to the results of AABB's 2007 Educational Needs Assessment. Geared toward individuals, this series highlights topics including performance reviews and setting employee performance expectations, coaching and feedback, employee development and managing a diverse workforce.

You must be a registered attendee to receive continuing education credit.

For more information about the AABB Leadership Management Audioconference Series, visit us online at www.aabb.org > Meetings and Events > Audioconferences

Questions?

Contact the AABB Education Department at +1.301.215.6482 or education@aabb.org

The topics for this year are:

Setting Employee Performance Expectations
January 13, 2009

Ongoing Employee Performance Review, Coaching and Feedback
May 19, 2009

Employee Development
September 15, 2009

Managing Employees of Different Cultural Backgrounds, Generations, and Communication Styles
November 17, 2009

recognition

AABB would like to thank the members of the AABB Distance Learning Program Unit for their assistance in developing these programs:

Jennifer F. Rhamy, MBA, MA, MT(ASCP)SBB, HP
Chair, AABB Distance Learning Program Unit
Vice President, Lab Services
Indiana Blood Center

Sue Connor, MBGM, MT(ASCP)SBB
Director of Physician Relations
John C. Lincoln Hospitals

Patricia Jost Golden, RN HP(ASCP)

Denise M. Harmening, PhD, MT(ASCP), CLS(NCA)
Professor
University of Maryland School of Medicine

Dennis Harpool, MT(ASCP)SBB
VP, Manufacturing Systems
Blood Systems, Inc.

Jay H. Herman, MD
Director, Transfusion Medicine
Thomas Jefferson University Hospital

Lorne Holland, MD
Associate Director of Transfusion Medicine
University of Colorado

Jerry A. Holmberg, PhD, MT(ASCP)SBB
Senior Advisor for Blood Safety and Executive Secretary
Advisory Committee on Blood Safety and Availability

Loyce Holmes, MSM-PM
Director, Business Design
Heamonetics Corporation

Veronica Lewis, MS, MT(ASCP)SBB
Assistant Professor
Rush University

Shelvi T. McFadden, MT(ASCP)
Technical Specialist
St. Vincent's Medical Center

Laurie McGraw, MS, MT(ASCP)SBB, CPLP
Director of Education and Training
Gulf Coast Regional Blood Center

Janet L. Vincent, MS, SBB(ASCP)
Education Coordinator
University of Texas Medical Branch

Kristina L. Williams, MT(ASCP)SBB, CQA, CQIA(ASQ)
Manager, Biomedical Headquarters IRL Operational Support
American Red Cross

www.aabb.org > Professional development > Live Learning Center

E-mail: education@aabb.org

Phone: +1.301.215.6482

Advancing Transfusion and
Cellular Therapies Worldwide

8101 Glenbrook Road
Bethesda, MD
20814-2749
USA

AABB Audioconferences:

Delivering Quality Education Directly to Your Facility… and to You